Stocks making the biggest moves midday: Block, SolarEdge, Cleveland-Cliffs, Verizon & more

Midday market activity was characterized by significant company-specific catalysts, with Bruker shedding 12% on weaker-than-expected Q2 guidance and Sarepta Therapeutics falling 7% after the FDA withdrew support for its gene therapy due to a patient death, impacting other biotech stocks. Conversely, Block surged 8% ahead of its S&P 500 inclusion, while Verizon gained 5% after surpassing Q2 earnings and revenue estimates. Cleveland-Cliffs also rose 13% on an improved capital expenditure outlook, illustrating diverse reactions to corporate performance and strategic developments.

Analysis

The midday market session reveals significant divergence driven by company-specific news, with the biotech and technology sectors experiencing notable volatility. Bruker (BRKR) saw its stock decline 12% after issuing second-quarter guidance of 32-34 cents per share on approximately $796 million in revenue, substantially missing analyst expectations of 42 cents per share and $813.3 million. The biotech sector faced heavy pressure after the FDA withdrew support for Sarepta Therapeutics' (SRPT) gene therapy, Elevidys, following a patient death, causing SRPT to fall 7% and triggering a nearly 12% drop in Arrowhead Pharmaceuticals (ARWR) and a 9% loss for Alkermes (ALKS) on disappointing trial data. Conversely, Block (SQ) surged 8% on the news of its upcoming inclusion in the S&P 500. Positive earnings and operational updates also fueled gains, with Verizon (VZ) rising 5% after beating Q2 estimates with $1.22 EPS on $34.5 billion in revenue. Cleveland-Cliffs (CLF) jumped 13% as its forecast for lower capital expenditures overshadowed a wider-than-expected quarterly loss, indicating investor focus on future cash flow. Analyst upgrades provided further tailwinds, lifting Pinterest (PINS) over 2% and Dollar Tree (DLTR) by 2.2%, while a price target increase boosted SolarEdge (SEDG) by 8%, though the article notes potential political headwinds for the solar sector.

Key Decisions for Investors

• Re-evaluate exposure to the biotech sector, particularly for companies with binary regulatory events, as the Sarepta news underscores the significant downside risk from adverse FDA decisions and its contagion effect.
• Prioritize forward-looking guidance and management commentary on cost controls over backward-looking earnings, as demonstrated by the market rewarding Cleveland-Cliffs for its improved capex outlook despite an earnings miss, while punishing Bruker for weak forward guidance.
• For event-driven rallies, such as Block's S&P 500 inclusion, investors should assess whether the price move is a temporary technical effect or supported by underlying fundamentals.
• When considering stocks boosted by analyst upgrades like Pinterest or SolarEdge, weigh the specific catalysts against broader industry headwinds, such as the noted political risks facing the solar sector.
• Companies demonstrating strong execution, like Verizon with its top and bottom-line beat, may represent more defensive positions in a market reacting sharply to individual corporate developments.